Literature DB >> 21117066

Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization.

William D Tap1, Fritz C Eilber, Charles Ginther, Sarah M Dry, Nicholas Reese, Kate Barzan-Smith, Hsiao-Wang Chen, Hong Wu, Frederick R Eilber, Dennis J Slamon, Lee Anderson.   

Abstract

Well-differentiated/de-differentiated liposarcomas (WDLS/DDLS) encompass an intriguing disease model in which a temporal intersection occurs between the malignant transformation of mesenchymal cells and the process of adipogenesis. Deciphering the molecular events that trigger and are characteristic of the intersection of these oncogenic and normal processes is critical to affect the often morbid and lethal consequences of malignant tumors of fat. High-resolution genome-wide oligonucleotide array-based comparative genomic hybridization (aCGH) with matched gene expression analyses was performed on seven lipomas, one hibernoma, and 38 WD and DDLS to define and compare the genomic events associated with these tumors. WD and DDLS had complex karyotypes. On average, WDLS had 11.1 and DDLS had 22.7 chromosomal copy number aberrations. All of the liposarcomas had 12q13-q15 amplifications with varying peaks at CDK4 (12q14.1), HMGA2 (12q14.3), and MDM2 (12q15); 24% of the DDLS and no WDLS had 1p32.2 (JUN) amplifications; 33% WDLS and 35% DDLS had 1q24.3 amplifications involving DNM3 and miR-214/miR-199a2; 24% of the liposarcomas had 6q23-q24 amplifications (including MAP3K5). Amplifications in GLI1 (12q13.3), JUN, and MAP3K5 (6q23.3) were mutually exclusive and occurred predominately in the DDLS. 6q amplifications occurred primarily in retroperitoneal tumors and females represented the majority of those patients who developed fatty tumors prior to the age of 50 years old. This detailed genetic mapping provides insight into the heterogeneity of WD and DDLS and the chromosomal and genetic abnormalities that are present in and distinguish these mesenchymal malignancies.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21117066     DOI: 10.1002/gcc.20835

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  28 in total

Review 1.  Role of genetic and molecular profiling in sarcomas.

Authors:  Scott M Norberg; Sujana Movva
Journal:  Curr Treat Options Oncol       Date:  2015-05

2.  Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment.

Authors:  Daniel Braas; Ethan Ahler; Brenna Tam; David Nathanson; Mirielle Riedinger; Matthias R Benz; Kathleen B Smith; Fritz C Eilber; Owen N Witte; William D Tap; Hong Wu; Heather R Christofk
Journal:  Cancer Discov       Date:  2012-12       Impact factor: 39.397

3.  Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition.

Authors:  Kathleen B Smith; Linh M Tran; Brenna M Tam; Elizabeth M Shurell; Yunfeng Li; Daniel Braas; William D Tap; Heather R Christofk; Sarah M Dry; Fritz C Eilber; Hong Wu
Journal:  Am J Pathol       Date:  2013-02-12       Impact factor: 4.307

4.  Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.

Authors:  Kentaro Igarashi; Kei Kawaguchi; Tasuku Kiyuna; Kentaro Miyake; Takashi Higuchi; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Shree Ram Singh; Hiroyuki Tsuchiya; Robert M Hoffman
Journal:  Cancer Genomics Proteomics       Date:  2020 Jul-Aug       Impact factor: 4.069

5.  A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions.

Authors:  Florence Pedeutour; Georges Maire; Anne Pierron; David M Thomas; Dale W Garsed; Laurence Bianchini; Valérie Duranton-Tanneur; Annabelle Cortes-Maurel; Antoine Italiano; Jeremy A Squire; Jean-Michel Coindre
Journal:  Virchows Arch       Date:  2012-06-08       Impact factor: 4.064

6.  Predicting dedifferentiation in liposarcoma: a proteomic approach.

Authors:  Colt M McClain; David B Friedman; Tahar Hajri; Cheryl M Coffin; Justin M M Cates
Journal:  Virchows Arch       Date:  2013-05-26       Impact factor: 4.064

7.  Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.

Authors:  Mark A Dickson; Gary K Schwartz; Mary Louise Keohan; Sandra P D'Angelo; Mrinal M Gounder; Ping Chi; Cristina R Antonescu; Jonathan Landa; Li-Xuan Qin; Aimee M Crago; Samuel Singer; Andrew Koff; William D Tap
Journal:  JAMA Oncol       Date:  2016-07-01       Impact factor: 31.777

8.  Plasma levels of miRNA-155 as a powerful diagnostic marker for dedifferentiated liposarcoma.

Authors:  Aleksandar Boro; David Bauer; Walter Born; Bruno Fuchs
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

9.  Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.

Authors:  Esma Saâda-Bouzid; Fanny Burel-Vandenbos; Dominique Ranchère-Vince; Isabelle Birtwisle-Peyrottes; Bruno Chetaille; Corinne Bouvier; Marie-Christine Château; Michel Peoc'h; Maxime Battistella; Audrey Bazin; Jocelyn Gal; Jean-François Michiels; Jean-Michel Coindre; Florence Pedeutour; Laurence Bianchini
Journal:  Mod Pathol       Date:  2015-09-04       Impact factor: 7.842

10.  Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

Authors:  Mark A Dickson; William D Tap; Mary Louise Keohan; Sandra P D'Angelo; Mrinal M Gounder; Cristina R Antonescu; Jonathan Landa; Li-Xuan Qin; Dustin D Rathbone; Mercedes M Condy; Yelena Ustoyev; Aimee M Crago; Samuel Singer; Gary K Schwartz
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.